Anti-Ang2 antibody

Patent metadata

Field	Value
Publication number	US-9828422-B2
Application number	US-201414446228-A
Country	US
Kind code	B2
Filing date	Jul 29, 2014
Priority date	Jul 29, 2013
Publication date	Nov 28, 2017
Grant date	Nov 28, 2017

Abstract

An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor and Ang2, and related methods and compositions.

First claim

What is claimed is:

1. An anti-Ang2 antibody or an antigen-binding fragment thereof which comprises heavy chain complementarity determining regions (CDRs) comprising a polypeptide (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 1, a polypeptide (CDR-H2) comprising the amino acid sequence of SEQ ID NO: 2, and a polypeptide (CDR-H3) comprising the amino acid sequence of SEQ ID NO: 3; and
light chain complementarity determining regions comprising a polypeptide (CDR-L1) comprising the amino acid sequence of SEQ ID NO: 4, a polypeptide (CDR-L2) comprising the amino acid sequence of SEQ ID NO: 5, and a polypeptide (CDR-L3) comprising the amino acid sequence of SEQ ID NO: 6.

2. The anti-Ang2 antibody or an antigen-binding fragment thereof according to claim 1 , comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9.

3. The anti-Ang2 antibody or an antigen-binding fragment thereof according to claim 1 , wherein the anti-Ang2 antibody is a monoclonal antibody.

4. The anti-Ang2 antibody or an antigen-binding fragment thereof according to claim 3 , wherein the anti-Ang2 antibody is obtained from a hybridoma deposited with accession number KCLRF-BP-00295.

5. A hybridoma cell line of accession number KCLRF-BP-00295.

6. A complex comprising the anti-Ang2 antibody or an antigen-binding fragment thereof of claim 1 , Ang2, and a Tie2 receptor.

7. A conjugate comprising the anti-Ang2 antibody or an antigen-binding fragment thereof of claim 1 bound to Ang2.

8. A pharmaceutical composition comprising the anti-Ang2 antibody or an antigen-binding fragment thereof of claim 1 .

9. A method of treating a cancer that expresses Ang2 in a subject, comprising administering the anti-Ang2 antibody or an antigen-binding fragment thereof of claim 1 to the subject.

10. A method of treating cancer metastasis in a subject comprising administering to the subject the anti-Ang2 antibody or an antigen-binding fragment thereof of claim 1 .

11. The method according to claim 9 , further comprising administering Ang2 to the subject.

12. The method according to claim 10 , further comprising administering Ang2 to the subject.

Assignees

• Samsung Electronics Co Ltd

Inventors

• Kim Kyung Eun
• Oh Seung Ja
• Lee Hyo Seon
• Han Sang Yeul

Classifications

• C07K2317/74

  Inducing cell proliferation · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61K39/395

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/77

  Internalization into the cell · CPC title